EPISODE · Feb 27, 2026 · 38 MIN
Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
from Decera Clinical Education Oncology Podcast · host Ibrahim Aldoss MD, Bijal Shah MD
In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
In this episode, 2 experts discuss how immunotherapy has reshaped the treatment landscape of acute lymphoblastic leukemia (ALL), highlighting advances in bispecific antibodies, CAR T-cell therapies, and MRD-guided strategies in both frontline and relapsed/refractory settings. They also explore evolving decisions around toxicity, treatment sequencing, transplant, and the promise of more effective, less burdensome approaches that may further improve long-term outcomes.
NOW PLAYING
Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.